Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas

Neoplasia

Volumn 10, Issue 9, 2008, Pages 1021-1027

  Weichert, Wilko ^a   Denkert, Carsten ^a   Noske, Aurelia ^a   Darb Esfahani, Silvia ^a   Dietel, Manfred ^a   Kalloger, Steve E ^b   Huntsman, David G ^b   Köbel, Martin ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SALPINGOOOPHORECTOMY;

EID: 50949104573     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08474     Document Type: Article

References (38)

1. Winter WE III, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, Markman M, Armstrong DK, Muggia F, McGuire WP, et al. (2007). Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25, 3621-3627.
2. Kristensen GB, Kildal W, Abeler VM, Kaern J, Vergote I, Tropé CG, and Danielsen HE (2003). Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer. Ann Oncol 14, 1494-1500.
3. Soslow RA, Bissonnette JP, Wilton A, Ferguson SE, Alektiar KM, Duska LR, and Oliva E (2007). Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. Am J Surg Pathol 31, 979-987.
4. Fujii H, Matsumoto T, Yoshida M, Furugen Y, Takagaki T, Iwabuchi K, Nakata Y, Takagi Y, Moriya T, Ohtsuji N, et al. (2002). Genetics of synchronous uterine and ovarian endometrioid carcinoma: combined analyses of loss of heterozygosity, PTEN mutation, and microsatellite instability. Hum Pathol 33, 421-428.
5. Gilks CB, Ionescu DN, Kalloger SE, Köbel M, and Swenerton K (2008). Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 39, 1239-1251.
6. Köbel M, Langhammer T, Hüttelmaier S, Schmitt WD, Kriese K, Dittmer J, Strauss HG, Thomssen C, and Hauptmann S (2006). Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas. Mod Pathol 19, 581-587.
7. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, De Winter KA, Lutgens LC, van den Bergh AC, van de Steen-Banasik E, et al. (2000). Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 355, 1404-1411.
8. Swenerton KD (1992). Prognostic indices in ovarian cancer. Their significance in treatment planning. Acta Obstet Gynecol Scand Suppl 155, 67-74, and updated ovarian carcinoma treatment guidelines in British Columbia (http://www. bccancer.bc.ca/PPI/TypesofCancer/Ovary/default.htm).
9. Maggi R, Lissoni A, Spina F, Melpignano M, Zola P, Favalli G, Colombo A, and Fossati R (2006). Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 95, 266-271.
10. Yoo CB and Jones PA (2006). Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5, 37-50.
11. Minucci S and Pelicci PG (2006). Histone deacerylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6, 8-51.
12. Xu WS, Parmigiani RB, and Marks PA (2007). Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26, 5541-5552.
13. Bolden JE, Peart MJ, and Johnstone RW (2006). Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5, 769-784.
14. Candelaria M, Gallardo-Rincon D, Arce C, Cetina L, Aguilar-Ponce JL, Arrieta O, González-Fierro A, Chávez-Bianco A, de la Cruz-Hernández E, Camargo MF, et al. (2007). A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol 18, 1529-1538.
15. Marks PA and Breslow R (2007). Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25, 84-90.
16. Zhou XC, Dowdy SC, Podratz KC, and Jiang SW (2007). Epigenetic considerations for endometrial cancer prevention, diagnosis and treatment. Gynecol Oncol 107, 143-153.
17. Takai N and Narahara H (2007). Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis. Curr Med Chem 14, 2548-2553.
18. Ahn MY, Jung JH, Na YJ, and Kim HS (2008). A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells. Gynecol Oncol 108, 27-33.
19. Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, Miyakawa I, and Koeffler HP (2004). Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 10, 1141-1149.
20. Jiang S, Dowdy SC, Meng XW, Wang Z, Jones MB, Podratz KC, and Jiang SW (2007). Histone deacetylase inhibitors induce apoptosis in both type I and type II endometrial cancer cells. Gynecol Oncol 105, 493-500.
21. Takai N, Kawamata N, Gui D, Said JW, Miyakawa I, and Koeffler HP (2004). Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 101, 2760-2770.
22. Strait KA, Dabbas B, Hammond EH, Warnick CT, Iistrup SJ, and Ford CD (2002). Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins. Mol Cancer Ther 1, 1181-1190.
23. Khabele D, Son DS, Parl AK, Goldberg GL, Augenlicht LH, Mariadason JM, and Rice VM (2007). Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy. Cancer Biol Ther 6, 795-801.
24. Cooper AL, Greenberg VL, Lancaster PS, van Nagell JR Jr, Zimmer SG, and Modesitt SC (2007). In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer. Gynecol Oncol 104, 596-601.
25. Sonnemann J, Gänge J, Pilz S, Stötzer C, Ohlinger R, Belau A, Lorenz G, and Beck JF (2006). Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients. BMC Cancer 6, 183.
26. 2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-telated protein Bad. Mol Cancer Ther 4, 603-611.
27. Ozaki KI, Kishikawa F, Tanaka M, Sakamoto T, Tanimura S, and Kohno M (2008). Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs. Cancer Sci 99, 376-384.
28. Weichert W, Röske A, Gekeler V, Beckers T, Ebert MP, Pross M, Dietel M, Denkert C, and Röcken C (2008). Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 9, 139-148.
29. Weichert W, Roeske A, Niesporek S, Noske A, Buckendahl AC, Dietel M, Gekeler V, Boehm M, Beckers T, and Denkert C (2008). Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer - specific role of class I HDACs in vitro and in vivo. Clin Cancer Res 14, 1669-1677.
30. Weichert W, Röske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M, et al. (2008). Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 98, 604-610.
31. Krusche CA, Vloet AJ, Classen-Linke I, von Rango U, Beier HM, and Alfer J (2007). Class I histone deacetylase expression in the human cyclic endometrium and endometrial adenocarcinomas. Hum Reprod 22, 2956-2966.
32. Prentice LM, Klausen C, Kalloger S, Köbel M, McKinney S, Santos JL, Kenney C, Mehl E, Gilks CB, Leung P, et al. (2007). Kisspeptin and GPR54 immuno-reactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma. BMC Med 5, 33.
33. Alkushi A, Clarke BA, Akbari M, Makretsov N, Lim P, Miller D, Magliocco A, Coldman A, van de Rijn M, Huntsman D, et al. (2007). Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. Mod Pathol 20, 1156-1165.
34. Krusche CA, Wülfing P, Kersting C, Vloet A, Böcker W, Kiesel L, Beier HM, and Alfer J (2005). Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat 90, 15-23.
35. Matias-Guiu X, Catasus L, Bussaglia E, Lagarda H, Garcia A, Pons C, Munoz J, Arguelles R, Machin P, and Prat J (2001). Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 32, 569-577.
36. Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, Hernandez NS, Chen X, Ahmed S, Konishi K, et al. (2007). Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA 104, 18654-18659.
37. Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, et al. (2003). Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 95, 113-125.
38. Ropero S, Fraga MF, Ballestar E, Hamelin R, Yamamoto H, Boix-Chornet M, Caballero R, Alaminos M, Setien F, Paz MF, et al. (2006). A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet 38, 566-569.